PKU (phenylketonuria) is diagnosed through a routine blood test performed on nearly every newborn in the United States, typically between 24 and 48 hours after birth. This screening catches the condition before symptoms develop, which is critical because early treatment prevents the serious intellectual disabilities PKU can cause. If the initial screen comes back positive, confirmatory blood tests follow to measure exact phenylalanine levels and determine the severity.
The Newborn Heel Prick Test
The first step in diagnosing PKU happens in the hospital before you take your baby home. Between 24 and 48 hours after birth, a healthcare provider pricks your newborn’s heel and collects a few drops of blood onto small circles on a special card. This blood spot screening, sometimes called the “heel stick” or “24-hour test,” checks for dozens of serious conditions at once, PKU among them.
The timing matters. Testing too early, before the baby has had enough feedings, can produce inaccurate results because phenylalanine levels need time to build up in the blood after the baby starts consuming protein from breast milk or formula. That 24-hour minimum window gives the body enough exposure to protein for the test to detect abnormal phenylalanine levels reliably. Some states require a second screening at one to two weeks of age as an added safety net.
What Happens After a Positive Screen
A positive newborn screen does not mean your baby definitely has PKU. It means phenylalanine levels were high enough to warrant a closer look. The next step is confirmatory testing, which typically involves a blood draw to measure the precise concentration of phenylalanine in your baby’s plasma. Urine tests may also be used.
Normal phenylalanine levels fall between roughly 35 and 120 µmol/L. In classic PKU, the most severe form, levels rise above 1,200 µmol/L. Milder forms fall somewhere in between. The 2023 clinical guideline from the American College of Medical Genetics and Genomics (ACMG) uses 360 µmol/L as a key threshold: anyone with untreated levels above that number is recommended for lifelong treatment, and maintaining levels at or below 360 µmol/L is strongly recommended for the best intellectual outcomes.
These confirmatory results help doctors categorize the condition’s severity and plan the right level of dietary management from the start.
Ruling Out BH4 Deficiency
About 3% of infants who show high phenylalanine on screening don’t actually have classic PKU. Instead, they have a problem with a helper molecule called BH4 (tetrahydrobiopterin) that the body needs to process phenylalanine. BH4 deficiency requires different treatment than PKU, so distinguishing between the two is an important part of the diagnostic workup.
To tell them apart, doctors may perform a BH4 loading test: the infant is given a dose of BH4 by mouth, and phenylalanine levels are measured before and after. If levels drop significantly, it suggests the child may respond to BH4 supplementation rather than needing a strict low-phenylalanine diet alone. Interestingly, about two-thirds of patients with mild PKU also respond to BH4, which can expand their treatment options beyond diet alone.
Genetic Testing
Genetic testing looks directly at the PAH gene, which provides instructions for the enzyme that breaks down phenylalanine. Mutations in this gene are the root cause of PKU. According to the NIH, genetic testing isn’t required to confirm a PKU diagnosis since blood phenylalanine levels alone can do that. But it serves several purposes that make it valuable.
First, identifying the specific mutations helps predict how severe the condition will be. Different mutations affect the enzyme to different degrees, and knowing which ones your child carries gives doctors a clearer picture of what to expect. Second, genetic testing is the primary tool for carrier detection. If one child in a family has PKU, testing can determine whether siblings or other relatives carry one copy of the mutated gene, which is useful information for family planning. Third, molecular testing of the PAH gene can definitively confirm that the elevated phenylalanine is caused by a PAH enzyme problem rather than a BH4 issue.
Prenatal Diagnosis
For families with a known history of PKU, testing before birth is possible. Two procedures can identify PKU in a developing fetus. Amniocentesis involves inserting a needle through the mother’s abdomen to collect a small sample of the amniotic fluid surrounding the baby. Chorionic villus sampling (CVS) takes a tiny tissue sample from the placenta, either through a needle in the abdomen or a tube inserted through the vagina. Both samples contain fetal DNA that can be analyzed for PAH gene mutations.
Prenatal testing is typically offered when both parents are known carriers, meaning each has one copy of the mutated gene. It gives families time to prepare for early dietary intervention, which ideally begins within the first days of life.
Why Early Detection Changes Everything
PKU causes no visible symptoms at birth. Without screening, the damage from phenylalanine buildup in the brain accumulates silently over weeks and months, eventually causing irreversible intellectual disability, seizures, and behavioral problems. Newborn screening flips that timeline completely. Babies identified in the first few days of life and started on a low-phenylalanine diet can develop normally and maintain healthy brain function throughout their lives.
The ACMG’s 2023 guideline emphasizes that treatment isn’t just for childhood. Keeping phenylalanine at or below 360 µmol/L is recommended as a lifelong goal. For women with PKU, achieving this level before conception is strongly recommended to prevent complications during pregnancy and protect the developing baby from high maternal phenylalanine, a condition known as maternal PKU syndrome that can cause heart defects and developmental problems in the child even if the child doesn’t have PKU themselves.